BioNexus Gene Lab Inventory 2019-2024 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNexus Gene Lab inventory from 2019 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNexus Gene Lab inventory from 2019 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$125.1B
Cencora (COR)	$45B
ICON (ICLR)	$25B
DiDi Global (DIDIY)	$19B
Avantor (AVTR)	$18.4B
Natera (NTRA)	$15.7B
Revvity (RVTY)	$15.4B
Viatris (VTRS)	$14.2B
CochLear (CHEOY)	$12.8B
Solventum (SOLV)	$12.5B
Medpace Holdings (MEDP)	$11.2B
Charles River Laboratories (CRL)	$10.6B
Sonic Healthcare (SKHHY)	$8.8B
Doximity (DOCS)	$7.4B
Bausch + Lomb (BLCO)	$7B
HealthEquity (HQY)	$6.8B
PACS (PACS)	$6.2B
Organon (OGN)	$5.1B
Life Times (LTH)	$4.9B
Sotera Health (SHC)	$4.7B
Surgery Partners (SGRY)	$4.1B
Concentras Parent (CON)	$3B
GoodRx Holdings (GDRX)	$2.8B
BrightSpring Health Services (BTSG)	$2.5B
Ardent Health Partners (ARDT)	$2.4B
Progyny (PGNY)	$2.2B
Alignment Healthcare (ALHC)	$2.2B
Premier (PINC)	$2.1B
Ryman Healthcare (RYHTY)	$1.9B
AMN Healthcare Services Inc (AMN)	$1.8B